Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer

Journal of Clinical Oncology

Volumn 35, Issue 7, 2017, Pages 804-805

  Lambertini, Matteo ^a   Falcone, Tommaso ^b   Unger, Joseph M ^c   Phillips, Kelly Anne ^d   Del Mastro, Lucia ^e   Moore, Halle C F ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GONADORELIN AGONIST; GONADORELIN;

BREAST CANCER; CANCER CHEMOTHERAPY; EARLY MENOPAUSE; FERTILITY; HUMAN; LETTER; OVARIAN PRESERVATION; OVARY FUNCTION; PREGNANCY RATE; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); FEMALE; LYMPHOMA; NEOPLASM; PROSPECTIVE STUDY; SURVIVOR;

FEMALE; FERTILITY; GONADOTROPIN-RELEASING HORMONE; HUMANS; LYMPHOMA; NEOPLASMS; PROSPECTIVE STUDIES; SURVIVORS;

EID: 85014022570     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.2582     Document Type: Letter

References (10)

1. Moore HCF, Unger JM, Phillips K-A, et al: Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923-932, 2015
2. Lambertini M, Boni L, Michelotti A, et al: Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: A randomized clinical trial. JAMA 314:2632-2640, 2015
3. Demeestere I, Brice P, Peccatori FA, et al: No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: Final long-term report of a prospective randomized trial. J Clin Oncol 34:2568-2574, 2016
4. Lambertini M, Ceppi M, Poggio F, et al: Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies. Ann Oncol 26:2408-2419, 2015
5. Paluch-Shimon S, Pagani O, Partridge AH, et al: Second international consensus guidelines for breast cancer in young women (BCY2). Breast 26:87-99, 2016
6. Oktay K, Bedoschi G: Appraising the biological evidence for and against the utility of GnRHa for preservation of fertility in patients with cancer. J Clin Oncol 34:2563-2565, 2016
7. Hamy A-S, Porcher R, Eskenazi S, et al: Anti-Müllerian hormone in breast cancer patients treated with chemotherapy: A retrospective evaluation of subsequent pregnancies. Reprod Biomed Online 32:299-307, 2016
8. Moore HC, Unger JM, Albain KS: Ovarian protection during adjuvant chemotherapy. N Engl J Med 372:2269-2270, 2015
9. Gordon A, Garrido-Gracia JC, Aguilar R, et al: Understanding the regulation of pituitary progesterone receptor expression and phosphorylation. Reproduction 149:615-623, 2015
10. Demeestere I, Brice P, Peccatori FA, et al: Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 31:903-909, 2013